The Interim report for Q2 2025 for Induct AS has been approved by the Board of Directors.
- EBITDA decreased to NOK 3,35 in Q2 2025 from NOK 3,73 million in Q2 2024 but increased by NOK 0,35 million compared to Q1 2025.
- Total operating costs increased to NOK 1,2 million in Q2 2025 from NOK 1,18 million in Q2 2024.
- Our partnership and collaboration discussions AstraZeneca and Portsmouth are progressing very well and there is a joint intention to expand the Severe Asthma module across England, but also the UK.
- Direct dialogue between Induct and AstraZeneca to assess other partnership opportunities.
- Continued focus on increasing revenues to strengthen our EBITDA further and deliver solid financial results.
- Goal to expand our technology and provide digital clinical pathways to other diseases, including diabetes and cardiovascular diseases, to name a few, each of which has the same, or larger, global revenue potential than severe asthma.